Articles Referencing RPRX

Zacks.com

Repros to Conduct Phase IIb Trial - Analyst Blog

Recently, the US Food and Drug Administration (FDA) recommended Repros Therapeutics Inc. ( RPRX ) to conduct a phase IIb trial on its pipeline candidate, Proellex-V before commencing phase... Read >>

Zacks.com

Repros Gets Additional Patents - Analyst Blog

Repros Therapeutics Inc. ( RPRX ) recently announced that two additional patents covering its candidate, Androxal, have been issued. Both patents (8,372,887 and 8,377,991) related to... Read >>

Zacks.com

Positive Data on Repros' Androxal - Analyst Blog

Repros Therapeutics Inc. ( RPRX ) recently provided top-line results from the ZA-301 study on its late-stage candidate, Androxal, which is being evaluated for the treatment of secondary... Read >>

Zacks.com

Repros Delays ZA-301 Study Results - Analyst Blog

Repros Therapeutics Inc. ( RPRX ) recently announced that results from the first pivotal study (ZA-301) of Androxal will be declared in the third quarter of 2013 instead of the second... Read >>

Zacks.com

Repros Provides Androxal Update - Analyst Blog

Repros Therapeutics Inc. ( RPRX ) recently provided an update on its phase III program for Androxal. The candidate is being evaluated for the treatment of secondary hypogonadism. The... Read >>

Benzinga

The Strongest Small-Caps in the Market

Traders who are comfortable with a high level of risk/reward frequently will gravitate to the small-cap space where big gains (and losses) in a short amount of time are commonplace. One... Read >>

Kapitall

Options Market Picks: 9 Highly Liquid Stocks with Bullish Options Sentiment

( Written by Rebecca Lipman. List compiled by Eben Esterhuizen, CFA. Options data sourced from Schaeffer’s. Accounting data sourced from Google Finance. ) Stock options are interesting because... Read >>